Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.

Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Sprache

Datenbank

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 14 von 14, Suchdauer: 0.59s

1
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial

von Pett, Sarah ; Ford, Deborah ; Thomason, Margaret ; et al.

In The Lancet HIV June 2026 13(6):e367-e379
- View full text via DOI
Merkliste

2
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to

von Achida, Clinton Otieno ; Adhiambo, Dorcus ; Ahimbisibwe, Gideon ; et al.

In Contemporary Clinical Trials March 2026 162
- View full text via DOI
Merkliste

3
Novel and optimized diagnostics for pediatric TB in endemic countries: NOD-pedFEND study protocol

von Song, Rinn ; Bijker, Else Margreet ; Kisitu, Grace ; et al.

BMC Pediatrics. 25(1)
- Zum Volltext in PubMed Central
Merkliste

4
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial

von Abraham, Pattamukkil ; Abrams, Elaine ; Acero, Judith ; et al.

In The Lancet Child & Adolescent Health March 2026 10(3):189-202
- View full text via DOI
Merkliste

5
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial

von Giaquinto, Carlo ; Nardone, Alessandra ; Morkunaite, Gabija ; et al.

In eBioMedicine October 2025 120
- View full text via DOI
Merkliste

6
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to

von Achida, Clinton Otieno ; Adhiambo, Dorcus ; Agaba, Gerald Muzorah ; et al.

In Contemporary Clinical Trials August 2025 155
- View full text via DOI
Merkliste

7
Oral Swab Testing With Xpert MTB/RIF Ultra for the Diagnosis of Tuberculosis in Children Aged

von Khambati, Nisreen ; Moureen, Kanyange Angel ; Basile, Francesca Wanda ; et al.

Open Forum Infectious Diseases ; volume 12, issue 4 ; ISSN 2328-8957
- View full text via BASE
Merkliste

8
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

von Mehar (nee Abdulla), Amina Farhana ; Abraham, Pattamukkil ; Abrams, Elaine ; et al.

In The Lancet Child & Adolescent Health October 2023 7(10):718-727
- View full text via DOI
Merkliste

9
Retrospective cohort study of Advanced HIV disease among children and adolescents in Uganda: Characteristics, clinical outcomes, and rate of mortality.

von Epidu, Calvin ; Ssebunya, Rogers N. ; Makumbi, Freddrick E. ; et al.

PLoS ONE; 7/2/2026, Vol. 21 Issue 7, p1-12, 12p
- View full text via DOI
Merkliste

10
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

von Mehar (nee Abdulla), Amina Farhana ; Abraham, Pattamukkil ; Abrams, Elaine ; et al.

In The Lancet HIV September 2022 9(9):e638-e648
- View full text via DOI
Merkliste

11
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

von Mehar (nee Abdulla), Amina Farhana ; Abraham, Pattamukkil ; Abrams, Elaine ; et al.

In The Lancet HIV September 2022 9(9):e627-e637
- View full text via DOI
Merkliste

12
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

von Turkova, Anna ; White, Ellen ; Kekitiinwa, Adeodata R ; et al.

The Lancet Child & Adolescent Health , 7 (10) pp. 718-727. (2023)
- View full text via BASE
Merkliste

13
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

von Turkova, Anna ; Waalewijn, Hylke ; Chan, Man K ; et al.

The Lancet HIV (2022) (In press).

Schlagworte: Penta Foundation; ViiV Healthcare; UK Medical Research Council
- View full text via BASE
Merkliste

14
Researchers' perspectives on the use of material transfer agreements in biobanking research; a case of Uganda.

von Namuddu R ; Nabukenya S ; Balwa H ; et al.

BMC medical ethics [BMC Med Ethics] 2026 May 21. Date of Electronic Publication: 2026 May 21.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag